Change in the Supervisory Board at aap Implantate AG

aap Implantate AG / Change in the Supervisory Board at aap Implantate AG 
. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is 
solely responsible for the content of this announcement. 
 
   aap Implantate AG ("aap") announces that Ronald Meersschaert will resign 
from his office as a member of the Supervisory Board for personal 
reasons. His duties will conclude on 5 October 2016. Ronald Meersschaert 
was first elected as a member of aap's Supervisory Board by the annual 
general meeting in financial year 2009. His successor will be Ms. 
Jacqueline Rijsdijk (60), who was elected as a substitute member for Mr. 
Meersschaert. Jacqueline Rijsdijk is a Board Advisor in the Netherlands 
and member of several Supervisory Boards and control committees of 
reputable companies such as Deloitte Netherlands and Royal Cosun. 
 
   Biense Visser, Chairman of the Supervisory Board at 
   aap 
 
   , praises the work of Ronald Meersschaert over the past years: "We thank 
Ronald Meersschaert for his great commitment and the outstanding work 
for 
   aap 
 
   on the way to a focused trauma company in recent years. As a recognised 
financial expert and seasoned investor, he was always a competent and 
trusted contact for the Supervisory and Management Boards and made a 
significant contribution in both financial and strategic matters." 
 
 
 
   In addition Biense Visser welcomes Jacqueline Rijsdijk's acceptance of 
the Supervisory Board mandate: "Jacqueline Rijsdijk is a regarded Board 
Advisor with comprehensive economic and financial knowledge and an 
excellent network. We are very much looking forward to our cooperation 
and are sure that 
   aap 
 
   will benefit from her distinctive financial expertise and many years of 
experience." 
 
 
 
 
   About aap Implantate AG 
 
   aap Implantate AG is a globally operating medical device company 
headquartered in Berlin, Germany. The company develops, manufactures and 
markets trauma and biomaterials products for orthopedics. The trauma 
portfolio includes besides the innovative anatomical plating system 
LOQTEQ(R) a wide range of cannulated screws as well as standard plates 
and screws. In the biomaterials business the company is specialized on 
bone cements and mixing systems. In German-speaking countries aap 
Implantate AG directly sells its trauma products to hospitals, buying 
syndicates and hospital groups while it uses a broad network of 
distributors in more than 60 countries at the international level. In 
the biomaterials business sales are handled via OEM and private label 
cooperations with several selected international orthopedic and trauma 
companies. aap Implantate AG's stock is listed in the Prime Standard 
segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more 
information, please visit www.aap.de, or download the Company's investor 
relations app from the Apple's App Store or Google Play. 
 
   Forward-looking statement 
 
   This release may contain forward-looking statements based on current 
experience, estimates and projections of the management board and 
currently available information. They are not guarantees of future 
performance. Various known and unknown risks, uncertainties and other 
factors could lead to material differences between the actual future 
results, financial situation, development or performance of the company 
and the estimates given here. Many factors could cause the actual 
results, performance or achievements of aap to be materially different 
from those that may be expressed or implied by such statements. These 
factors include those discussed in aap's public reports. Forward-looking 
statements therefore speak only as of the date they are made. aap does 
not assume any obligation to update the forward-looking statements 
contained in this release or to conform them to future events or 
developments. 
 
   For inquiries please contact: aap Implantate AG, Fabian Franke, Investor 
Relations, Lorenzweg 5, 12099 Berlin, Germany 
 
   Tel.: [phone], fax: [phone], e-mail: [e-mail] 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: aap Implantate AG via Globenewswire 
 
   --- End of Message --- 
 
   aap Implantate AG 
 
   Lorenzweg 5 Berlin Germany 
 
   WKN: 506660;ISIN: DE0005066609; 
 
   Listed: Freiverkehr in Börse Stuttgart, 
 
   Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, 
 
   Freiverkehr in Börse Berlin, 
 
   Freiverkehr in Börse Düsseldorf, 
 
   Freiverkehr in Bayerische Börse München, 
 
   Freiverkehr in Niedersächsische Börse zu Hannover, 
 
   Prime Standard in Frankfurter Wertpapierbörse, 
 
   Regulierter Markt in Frankfurter Wertpapierbörse; 
 
 
  http://www.aap.de 
 

(END) Dow Jones Newswires

September 12, 2016 06:02 ET (10:02 GMT)